Titre du document / Document title

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study

Auteur(s) / Author(s)

CHEUNG Raphael C. ⁽¹⁾ ; MORRELL Jonathan M. ⁽²⁾ ; KALLEND David ⁽³⁾ ; WATKINS Claire ⁽³⁾ ; SCHUSTER Herbert ⁽⁴⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Southwestern Ontario Medical Education Network Windsor, Schulich School of Medicine, University of Western Ontario, Windsor, Ontario, CANADA
⁽²⁾ The Conquest Hospital, Hastings, East Sussex, ROYAUME-UNI
⁽³⁾ AstraZeneca, Alderley Park, Cheshire, ROYAUME-UNI
⁽⁴⁾ Humboldt University, Berlin, ALLEMAGNE

Résumé / Abstract

Background: Lipid ratios are clinically useful markers of coronary artery disease (CAD) risk. The effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on lipid ratios were investigated in the Measuring Effective Reductions in Cholesterol Using Rosuvastatin TherapY (MERCURY) I trial. Methods: This trial was conducted in 3140 hypercholesterolemic patients with CAD, atherosclerosis, type 2 diabetes mellitus, or a 20% 10-year risk for CAD. Patients were randomized to rosuvastatin 10 mg, atorvastatin 10 or 20 mg, simvastatin 20 mg, or pravastatin 40 mg for 8 weeks; all patients except those receiving rosuvastatin 10 mg either were switched to rosuvastatin 10 or 20 mg or remained on initial treatment for 8 more weeks. Results: At 8 weeks, reductions in total cholesterol (TC):high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol:HDL-C, non-HDL-C:HDL-C, and apolipoprotein (apo) B:apo A-I ratios with rosuvastatin 10 mg were significantly greater than those with atorvastatin 10 mg, atorvastatin 20 mg, simvastatin 20 mg, and pravastatin 40 mg (P<0.0001 for all). At week 16, switching to rosuvastatin 10 mg from atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg and to rosuvastatin 20 mg from atorvastatin 20 mg produced significantly greater reductions in all lipid ratios (P≤0.0001 for all). Switching to rosuvastatin 10 mg from atorvastatin 20 mg produced significantly greater reductions in TC:HDL-C (P<0.025) and apo B:apo A-I (P<0.01). Conclusions: Rosuvastatin 10 mg reduces lipid ratios more than equivalent and higher doses of other statins; switching to equal or lower doses of rosuvastatin produces significantly improved reductions in lipid ratios.

Revue / Journal Title

International journal of cardiology   ISSN 0167-5273   CODEN IJCDD5 

Source / Source

2005, vol. 100, n^o2, pp. 309-316 [8 page(s) (article)] (22 ref.)

Langue / Language

Anglais

Editeur / Publisher

Elsevier Science, Shannon, IRLANDE  (1981) (Revue)

Mots-clés anglais / English Keywords

Hyperlipoproteinemia ; Dyslipemia ; Metabolic diseases ; Lipoprotein ; Cholesterol ; Mercury ; Ratio ; Apolipoprotein ; Lipids ; Switching ; Cardiovascular disease ; Coronary heart disease ; Hypercholesterolemia ;

Mots-clés français / French Keywords

Hyperlipoprotéinémie ; Dyslipémie ; Métabolisme pathologie ; Lipoprotéine ; Cholestérol ; Mercure ; Ratio ; Apolipoprotéine ; Lipide ; Commutation ; Appareil circulatoire pathologie ; Cardiopathie coronaire ; Hypercholestérolémie ;

Mots-clés espagnols / Spanish Keywords

Hiperlipoproteinemia ; Dislipemia ; Metabolismo patología ; Lipoproteina ; Colesterol ; Mercurio ; Ratio ; Apolipoproteína ; Lípido ; Conmutación ; Aparato circulatorio patología ; Cardiopatía coronaria ; Hipercolesterolemia ;

Mots-clés d'auteur / Author Keywords

Statins ; Hypercholesterolemia ; Coronary artery disease ; Lipid ratio ;

Localisation / Location

INIST-CNRS, Cote INIST : 16457, 35400012537495.0180